Blog

SBC & Me How does secondary breast cancer affect your life? I do get exhausted, the tiredness suddenly hits me.

The Food and Drug Administration (FDA) is responsible for approving drugs for disease treatment in America. Typically, before a new cancer drug is approved for usage in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), which has a separate approval process, the drug will initially get approved for usage in America by the FDA first.

Can you tell me a little about yourself? I'm 25 years old and live in Newcastle Upon Tyne with my boyfriend Jake and our German Shepherd Luna.

SBC & Me Date of diagnosis? Secondary diagnosis, October 2020 Current treatment line?

The Make 2nds Count team, trustees and volunteers attended the Edinburgh Breast Cancer Special Symposium (EBCSS) on Saturday 25th February.The event hasn't been held for several years due to COVID, so there was a lot of interest now that it's finally back face to face. The biennial event brings together scientists, healthcare providers and patients to discuss the latest thinking in breast cancer.

SBC & Me Date of diagnosis? 2021 Current treatment line?

The Northern Ireland Cancer Registry at Queen's University Belfast will conduct this study after receiving funding from the charity Cancer Focus NI. This is the first study of its kind and by gathering information on the number of patients living with secondary breast cancer in NI it will help with the future planning of services that can support the needs of patients.

The government has scrapped the specific NHS England 10-year cancer strategy for a new blended 5-year Major Conditions Strategy. England’s health and social care secretary, Steve Barclay, told the House of Commons on 24 January that the Department of Health and Social Care is currently developing a new 5-year Major Conditions Strategy that will tackle the major conditions that contribute to the burden of disease in England.

SBC & Me Date of diagnosis? March 2017 Current treatment line?

When diagnosed with secondary breast cancer, all of the medical terminologies can be very overwhelming. This three part series of posts will tell you a little bit more about the main classifications of secondary breast cancer that are used to direct medical treatments.

At the beginning of February, Gilead Sciences announced that United States Food and Drug Administration (FDA) approval was obtained for Trodelvy® (sacituzumab govitecan-hziy). This is for HR+ HER2- metastatic patients who experience disease progression after hormone therapy and two or more systemic therapies (such as chemotherapies).

When diagnosed with secondary breast cancer, all of the medical terminologies can be very overwhelming. This three part series of posts will tell you a little bit more about the main classifications of secondary breast cancer that are used to direct medical treatments.

At the end of January, ORSERDU™ (elacestrant) received Food and Drug Administration (FDA) approval as a new oral treatment for ER+ HER2- metastatic breast cancer in the United States. Endocrine therapy (also known as hormone therapy), with either aromatase inhibitors (AI) or fulvestrant, plus a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor is the recommended first-line standard-of-care for metastatic ER+ HER2- breast cancer.

We are proud to launching our Clinical Trial Registry to expand on our Patient Trial Advocate service. Our esteemed chairperson, Proffessor David Cameron, comments on the project: “We realise that many patients with secondary breast cancer want, and deserve, the chance to consider taking part in a clinical trial.

SBC & Me Date of diagnosis? 27th September 2021, primary diagnosis following examination, mammogram, ultrasound and punch biopsy - IDC.